IXHL Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Stats
Today's Volume	3 792.00
Average Volume	322 232
Market Cap	36.50M
EPS	$0 ( 2024-02-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.61
ATR14	$0.0200 (0.89%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-21	Valentine Troy	Buy	670 000	Common Stock
2023-12-21	Widdows Peter	Buy	100 000	Common Stock
2023-12-21	Latham Joel	Buy	1 340 000	Common Stock
2023-12-21	Anastassov George	Buy	100 000	Common Stock
2023-12-21	Clark Robert	Buy	100 000	Common Stock

INSIDER POWER
89.24
Last 27 transactions
Buy: 2 310 000 \| Sell: 136 337

Incannex Healthcare Correlation

10 Most Positive Correlations
GNUS	0.919
CATB	0.915
TTOO	0.915
TUEM	0.913
LSXMA	0.911
LSXMK	0.91
AGEN	0.903
SIRI	0.902
ACRS	0.902
JKHY	0.897

10 Most Negative Correlations
EBSB	-0.892
CIIG	-0.891
CPTA	-0.883
SCR	-0.88
BTAQ	-0.878
GRIL	-0.876
ASRT	-0.874
PTOC	-0.873
FRSG	-0.873
GPACU	-0.871

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Incannex Healthcare Financials

Annual	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.420

FY	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.420

FY	2022
Revenue:	$0
Gross Profit:	$-6 338.00 (0.00 %)
EPS:	$-0.320

FY	2021
Revenue:	$1.90M
Gross Profit:	$985 628 (51.94 %)
EPS:	$-0.169

Financial Reports:

No articles found.

Incannex Healthcare

Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.